Gastroenterology -Therapeutics & Hepatology

Hepatitis C Therapeutics

Hepatitis C, a viral infection that causes liver inflammation, can lead to severe liver damage if left untreated. Recent advances in Hepatitis C therapeutics have revolutionized patient care, offering highly effective and well-tolerated treatment options. The development of direct-acting antivirals (DAAs) has been a game-changer, providing cure rates exceeding 95% with shorter treatment durations and fewer side effects compared to previous therapies. These medications target specific steps in the viral replication process, effectively eradicating the virus from the body. Combination therapies, such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, have simplified treatment protocols, making it easier for patients to adhere to the regimen. Additionally, ongoing research into pan-genotypic treatments aims to provide universal solutions across all Hepatitis C genotypes. Early diagnosis and access to these advanced therapeutics are crucial for preventing complications like cirrhosis and liver cancer, ultimately improving patient outcomes and quality of life for those affected by Hepatitis C.